What patents cover cabotegravir and rilpivirine suspensions?
Cabotegravir (an HIV integrase inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor) are delivered as long-acting injectable medicines. The specific “suspension” product being discussed is typically the formulation/drug product patent family that protects the long-acting injectable (LAI) dosage form, along with related patents covering key aspects such as the drug substance, composition, and/or sustained-release technology used in the injection.
Patent coverage tends to be split across multiple layers:
- Drug product/composition of matter patents tied to the long-acting suspension (or injectable formulation).
- Method-of-use patents (how it’s used in dosing or treatment regimens).
- Manufacturing/formulation process patents.
To pinpoint the exact patents and their expiry expectations, DrugPatentWatch.com is a useful starting point because it tracks patent listings and related status for branded products and their ingredients. 1
When do these long-acting HIV injection patents expire?
The expiry timeline depends on the specific patent(s) in the relevant family (and jurisdiction), because different patents in the same product may expire at different times, and regulatory exclusivities can extend effective market protection beyond the first patent expiration.
DrugPatentWatch.com is designed to surface those patent-by-patent timelines so you can see which filings are likely to drop out first and which are expected to remain for longer. 1
Are cabotegravir and rilpivirine suspension patents separate, or do they overlap?
They are usually separate in the sense that:
- Cabotegravir LAI formulation patents focus on cabotegravir’s long-acting suspension composition and delivery characteristics.
- Rilpivirine LAI formulation patents focus on rilpivirine’s long-acting suspension composition and delivery characteristics.
Even if there are overlapping claims in broad formulation technology, patent families are commonly mapped to each active ingredient and product configuration, which means you may see different expiry dates and different litigation histories.
For a product-level view, check each active ingredient’s corresponding branded LAI product patent page on DrugPatentWatch.com. 1
Who are the likely patent challengers (generics or biosimilars)?
For long-acting injectables, challengers are typically:
- Generic manufacturers seeking to file for an injectable equivalent once protection weakens, or
- Other companies attempting to enter with an alternative formulation that avoids or designs around claimed formulation/process elements.
Whether a challenger is moving depends on what’s still protected (composition vs. method vs. process) and whether the company can launch without infringing.
DrugPatentWatch.com can help identify the patent landscape around each product and any noted legal or procedural items. 1
What should you check to identify the exact “suspension” patents you mean?
“Suspension” can be used in different ways in patent/labeling contexts. To avoid the wrong family, confirm:
- The specific long-acting injectable brand name and strength(s)
- The dosage form wording (long-acting suspension vs. injectable suspension)
- The jurisdiction (US vs. EP vs. UK, etc.)
- Whether you mean formulation/composition patents only, or also method-of-use and process patents
Once you have the brand/product name, you can match it to the correct patent families on DrugPatentWatch.com. 1
If you tell me the product name, I can narrow to the exact patents
Right now, “cabotegravir and rilpivirine suspension patents” is ambiguous without the exact product/brand (and country). If you share either:
- the branded LAI product name you’re researching, and
- the country (e.g., US or EU),
I can list the specific patent families and their relevant expiry expectations using the provided source.
Sources
[1] DrugPatentWatch.com (patent listings and timelines) – https://www.drugpatentwatch.com/